ARROWHEAD PHARMACEUTICALS, INC. Deferred Tax Assets, Deferred Income
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) had Deferred Tax Assets, Deferred Income of $171.26 million as of 2025-09-30, per its 10-K filed 2025-11-25.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsDeferredIncome · last filed 2025-11-25
- 2025-09-30: Deferred Tax Assets, Deferred Income $171.26M.
- 2024-09-30: Deferred Tax Assets, Deferred Income $81.56M.
- 2023-09-30: Deferred Tax Assets, Deferred Income $59.44M.
- 2022-09-30: Deferred Tax Assets, Deferred Income $38.81M.
| Period end | Deferred Tax Assets, Deferred Income | Deferred Tax Assets, Deferred Income as first filed |
|---|---|---|
| 2025-09-30 | $171.26M 10-K · filed 2025-11-25 | |
| 2024-09-30 | $81.56M 10-K · filed 2025-11-25 | |
| 2023-09-30 | $59.44M 10-K · filed 2024-11-26 | |
| 2022-09-30 | $38.81M 10-K · filed 2023-11-29 | |
| 2021-09-30 | $0.00 10-K · filed 2022-11-28 | |
| 2020-09-30 | $1.70M 10-K · filed 2021-11-22 | $1.70M 10-K · filed 2020-11-23 |
| 2017-09-30 | $1.07M 10-K · filed 2018-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |